{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6","upperLimit":"25","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"The complete pathologic response (path CR) rate after treatment calculated as the percentage of participants with path CR out of the total participants, where the path CR is defined as absence of tumor cells in the surgical specimen and all registered participants are used in the denominator for calculating the path CR rate.\n\nPrimary gastric carcinoma is not measurable by conventional criteria thus usual response criteria cannot be applied. The following criteria for response assessment applied: Pathologic Complete Response: Absence of tumor cells in the surgical specimen, 95% or more necrosis of the cancer; Complete Clinical Response: Absence of tumor on endoscopy, biopsy, cytology, or both.","dispersionType":"95% Confidence Interval","groups":[{"description":"FOLFOX-48 PreOp Chemotherapy (2 Cycles) with oxaliplatin, folinic acid \\& infusional 5-FU repeated every 2 weeks x 4 (8 weeks of induction chemotherapy). PreOp Chemoradiotherapy following PreOp Chemo 5FU plus oxaliplatin for total 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m\\^2 for 5 days) \\& weekly oxaliplatin 45 mg/m\\^2 for 5 weeks (oxaliplatin administered on the first day of radiation week). Surgical resection 4-6 weeks after completion of chemoradiotherapy.","id":"OG000","title":"5-Fluorouracil + Folinic Acid + Oxaliplatin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Restaging and surgical resection at 4-6 weeks after completion of chemoradiotherapy, approximately at 16 weeks into treatment","title":"Complete Pathologic Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}